Catalent CEO to remain in charge of contract drugmaker

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
Catalent’s Maselli to continue as CEO post Novo Holdings deal close
Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli said,
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 billion deal will not raise competitive concerns.
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
Catalent issues letter to customers regarding acquisition by Novo Holdings
Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the
US Senator Warren Calls for Scrutiny of Novo Holdings' Catalent Deal
NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent, saying it may give the pharmaceutical company an unlawful advantage in obesity drugs.
Warren calls on FTC to scrutinize Novo Holdings' $16.5B Catalent buyout
As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S. Federal Trade Commission,
STAT4d
Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...
BioSpace4d
Unions, Public Interest Groups Call on FTC to Challenge Novo Holdings-Catalent Acquisition
Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging ...
FierceBiotech12d
Novo Holdings-backed Booster takes off with protein degraders aimed at neurodegeneration
Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...
Reuters5d
Consumer groups ask FTC to block Novo Holdings-Catalent deal
NEW YORK, Oct 18 (Reuters) - U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo ...
BioSpace11d
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
Novo Holdings leads $112M investment in Watertown biotech
A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...
FierceBiotech11h
AvenCell secures $112M series B to flick 'switchable' CAR-Ts in the clinic
AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...